Lilly's weight-loss drug Mounjaro officially launched in China
2025-01-02 09:11:48

Eli Lilly announced Thursday that tirzepatide (trade name: Mounjaro), glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, has been officially marketed in China covering two indications: type 2 diabetes and weight loss.

Mounjaro is currently available in China in four sizes, including 2.5 mg:0.5 ml, 5 mg:0.5 ml, 7.5 mg:0.5 ml, and 10 mg:0.5 ml.

It is the world's first and currently only once-weekly GIP/GLP-1 receptor agonist approved for type 2 diabetes and long-term weight management.

The weight-loss version of tirzepatide, with revenues of $3.018 billion in the first three quarters of 2024, is in the top tier of the global GLP-1 track with Novo Nordisk's GLP-1 drug semaglutide (trade name: Wegovy).

Previous media reports have mentioned that a number of Chinese e-commerce platforms already have diagnosis and pickup services for tirzepatide, with prices varying across the platforms' various merchants.

Email Subscription
Newsletters and emails are now available! Delivered on time, every weekday, to keep you up to date with North American business news.
ASIA TECH WIRE

Grasp technology trends

Download